Scholarlink

<p>Despite decades of significant progress in gastric cancer research, the prognosis remains poor because of the disease’s high aggressiveness. Historically, gastric cancers were classified based on histopathology and anatomical site—criteria that inadequately support precision therapy. Advances in molecular technologies have produced multiple molecular classification schemes, among which the Cancer Genome Atlas (TCGA) and the Asian Cancer Research Group (ACRG) classifications are the most mature and widely applied. In this review, we systematically summarize molecular subtypes of gastric cancer and explore their underlying molecular mechanisms, therapeutic implications, and prognostic associations. The evidence indicates that molecular subtyping is a key basis for improving precision therapy and enhancing patient outcomes: TCGA and ACRG provide clear clinical guidance, while emerging classifications offer new directions for individualized treatment and support the clinical translation of precision oncology in gastric cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Advances in the molecular subtyping of gastric cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月29日

查看全文
  • Jiayi Chen,
  • Xijie Zhang,
  • Yuzhou Zhao

摘要

Despite decades of significant progress in gastric cancer research, the prognosis remains poor because of the disease’s high aggressiveness. Historically, gastric cancers were classified based on histopathology and anatomical site—criteria that inadequately support precision therapy. Advances in molecular technologies have produced multiple molecular classification schemes, among which the Cancer Genome Atlas (TCGA) and the Asian Cancer Research Group (ACRG) classifications are the most mature and widely applied. In this review, we systematically summarize molecular subtypes of gastric cancer and explore their underlying molecular mechanisms, therapeutic implications, and prognostic associations. The evidence indicates that molecular subtyping is a key basis for improving precision therapy and enhancing patient outcomes: TCGA and ACRG provide clear clinical guidance, while emerging classifications offer new directions for individualized treatment and support the clinical translation of precision oncology in gastric cancer.